

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON&BIRD LLP

RECEIVED CENTRAL FAX CENTER

JUN 2 4 2004

101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 704-444-1000 Fax: 704-444-1111

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

June 24, 2004	
Recipient:	Company:
U.S. PATENT & TRADEMARK	
OFFICE	
Fax Number:	Voice Number;
(703) 872-9306	
Sender:	
Raymond O. Linker, Jr.	
Message:	
Application No. 10/069,913 OFFICIAL AFTER FINAL RESPONSE Number of Pages: (including cover page) 8 IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT.	
IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT.	
USER CODE: LINKR	REQUESTED BY: Jan Sherrill - 1163
CLIENT/MATTER: 033339/244859	OPERATOR:

Alston&Bird

Date:

PATENT

RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED PROCEDURE - EXAMINING GROUP 1623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.:

10/069,913

Confirmation No.: 7074

Applicant(s): Filed:

Colliec-Jouault et al. February 28, 2002

Art Unit:

1623

Examiner: Title:

Leigh C. Maier

USE OF A LOW MOLECULAR WEIGHT SULPHATED POLYSACCHARIDE

TO OBTAIN A MEDICINE WITH ANTITHROMBOTIC ACTIVITY

Docket No.:

033339/244859

Customer No.: 00826

RECEIVED CENTRAL FAX CENTER

JUN 2 4 2004

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL **PURSUANT TO 37 C.F.R. § 1.116**

Sir:

In response to the Office Action dated April 7, 2004, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.